Tyra Biosciences, Inc. $TYRA Shares Purchased by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Tyra Biosciences by 23.6%, owning 301,801 shares valued at approximately $2.8 million as of the latest SEC filing.
• A significant number of institutional investors have also boosted their holdings in Tyra Biosciences, with 84.14% of shares owned by institutions as of the last quarter.
• Recent stock analyst reports show a favorable outlook for Tyra Biosciences, with price targets as high as $35.00 and a consensus rating of "Buy."

Jacobs Levy Equity Management Inc. raised its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 23.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 301,801 shares of the company's stock after acquiring an additional 57,556 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.57% of Tyra Biosciences worth $2,807,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in TYRA. BNP Paribas Financial Markets bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $60,000. US Bancorp DE increased its holdings in shares of Tyra Biosciences by 50.5% during the 1st quarter. US Bancorp DE now owns 5,435 shares of the company's stock valued at $51,000 after purchasing an additional 1,823 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $84,000. Exchange Traded Concepts LLC increased its holdings in Tyra Biosciences by 42.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after acquiring an additional 3,550 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in Tyra Biosciences in the 4th quarter worth $171,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Insider Transactions at Tyra Biosciences

In related news, Director Gilla Kaplan sold 9,568 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total transaction of $93,575.04. Following the completion of the sale, the director owned 28,231 shares of the company's stock, valued at approximately $276,099.18. This represents a 25.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 16,392 shares of company stock worth $164,408. 15.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TYRA has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 price objective for the company. Oppenheimer reaffirmed an "outperform" rating and set a $36.00 target price on shares of Tyra Biosciences in a research note on Wednesday. Finally, Raymond James Financial began coverage on shares of Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, Tyra Biosciences presently has a consensus rating of "Buy" and a consensus price target of $31.86.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA traded up $0.05 during trading on Friday, hitting $12.52. 196,339 shares of the company were exchanged, compared to its average volume of 233,604. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60. The firm's fifty day moving average price is $11.19 and its 200 day moving average price is $10.28.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.06. Analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.